GHSI RSI Chart
Last 7 days
3.4%
Last 30 days
5.5%
Last 90 days
1.2%
Trailing 12 Months
35.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 12.1M | 0 | 0 | 0 |
2023 | 11.9M | 11.4M | 12.0M | 12.2M |
2022 | 9.4M | 11.4M | 11.0M | 11.0M |
2021 | 1.9M | 1.9M | 4.8M | 7.2M |
2020 | 906.1K | 1.8M | 1.9M | 1.9M |
2019 | 991.7K | 1.0M | 898.8K | 902.9K |
2018 | 574.5K | 735.3K | 966.8K | 942.2K |
2017 | 167.8K | 198.4K | 227.4K | 437.4K |
2016 | 119.9K | 126.9K | 134.0K | 141.0K |
2015 | 0 | 0 | 0 | 112.8K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 10, 2023 | radoff bradley louis | bought | 242,353 | 7.59727 | 31,900 | - |
Jan 09, 2023 | radoff bradley louis | bought | 583,487 | 6.87904 | 84,821 | - |
Jan 06, 2022 | scholtes bret | sold (taxes) | -24,163 | 0.65 | -37,175 | ceo and president |
Aug 31, 2021 | scholtes bret | bought | 6,760 | 1.2291 | 5,500 | ceo and president |
Aug 30, 2021 | gagliano donald a | bought | 6,250 | 1.25 | 5,000 | - |
Aug 30, 2021 | scholtes bret | bought | 5,655 | 1.2568 | 4,500 | ceo and president |
Aug 20, 2021 | weingarten robert n | acquired | 11,400 | 1.14 | 10,000 | - |
Jan 06, 2021 | scholtes bret | acquired | - | - | 916,023 | chief executive officer |
Jan 06, 2021 | scholtes bret | acquired | - | - | 152,671 | ceo and president |
Oct 30, 2019 | evans david w | acquired | 664 | 0.332 | 2,000 | chief science officer |
Which funds bought or sold GHSI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -12.3 | 2,930 | 9,007 | -% |
May 15, 2024 | Federation des caisses Desjardins du Quebec | new | - | 306 | 306 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 2,428 | 5,947 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | reduced | -0.53 | 138,000 | 341,000 | -% |
May 13, 2024 | UBS Group AG | new | - | 10,577 | 10,577 | -% |
May 13, 2024 | FMR LLC | new | - | 9.00 | 9.00 | -% |
May 10, 2024 | VANGUARD GROUP INC | unchanged | - | 54,729 | 134,039 | -% |
May 10, 2024 | BlackRock Inc. | unchanged | - | 36,961 | 90,521 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | unchanged | - | 22.00 | 54.00 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | unchanged | - | 33.00 | 81.00 | -% |
Unveiling Guardion Health Sciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Guardion Health Sciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Guardion Health Sciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 2.2% | 3,000 | 2,936 | 3,337 | 2,790 | 3,186 | 2,726 | 2,664 | 3,275 | 2,385 | 2,627 | 3,149 | 1,224 | 233 | 200 | 253 | 1,191 | 246 | 238 | 161 | 261 | 243 |
Gross Profit | -12.6% | 1,179 | 1,350 | 1,460 | 1,249 | 1,335 | 936 | 1,088 | 1,400 | 1,096 | 1,064 | 1,388 | 559 | 100 | -878 | 139 | 546 | 137 | 158 | 90.00 | 164 | 149 |
Operating Expenses | 12.2% | 2,733 | 2,436 | 2,233 | 2,262 | 2,799 | 12,286 | 2,828 | 3,111 | 3,717 | 15,585 | 4,404 | 5,099 | 2,770 | 2,477 | 2,291 | 1,255 | 2,473 | 4,247 | 2,503 | 2,976 | 1,331 |
S&GA Expenses | -2.8% | 362 | 372 | 319 | 415 | 599 | 486 | 526 | 389 | 669 | 609 | 778 | 441 | 458 | 275 | 167 | 519 | 489 | 646 | 448 | 409 | 354 |
R&D Expenses | 3884.9% | 3.00 | 79.50* | 11.00 | 77.00 | 63.00 | 31.00 | 60.00 | 96.00 | 7.00 | 11.00 | 16.00 | 17.00 | 21.00 | 51.00 | 34.00 | 45.00 | 31.00 | 56.00 | 32.00 | 78.00 | 29.00 |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.50* | 4.00 | 2.00 | 2.00 | 3.00 | 4.00 | 234 | 18.00 |
Income Taxes | - | - | - | - | - | - | -20.84 | - | - | - | - | - | 11.00 | 9.00 | - | - | - | - | - | - | - | - |
Net Income | -1217.6% | -4,746 | 425 | 373 | -1,172 | 533 | -12,453 | -822 | 3,656 | -5,300 | -14,520 | -3,014 | -4,540 | -2,669 | -3,374 | -2,143 | -707 | -2,346 | -4,055 | -2,385 | -3,052 | -1,385 |
Net Income Margin | -3391.0% | -0.42* | 0.01* | -1.06* | -1.22* | -0.77* | -1.35* | -1.55* | -1.68* | -2.92* | -3.42* | -2.83* | -6.66* | -4.74* | - | - | - | - | - | - | - | - |
Free Cashflow | 42.7% | -754 | -1,317 | -766 | -408 | -1,880 | -1,363 | -1,285 | -2,574 | -2,228 | -1,564 | -1,868 | -4,865 | -2,420 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -12.7% | 10,407 | 11,918 | 12,878 | 13,474 | 14,419 | 21,686 | 28,228 | 29,835 | 31,621 | 23,461 | 38,613 | 41,285 | 44,702 | 9,861 | 12,159 | 14,034 | 15,283 | 12,877 | 8,955 | 5,698 | 3,971 |
Current Assets | -12.6% | 10,382 | 11,885 | 12,840 | 13,431 | 14,373 | 21,637 | 17,811 | 19,099 | 20,568 | 12,069 | 14,867 | 16,547 | 43,996 | 9,095 | 11,334 | 13,171 | 14,303 | 11,868 | 6,132 | 2,856 | 544 |
Cash Equivalents | -11.9% | 5,605 | 6,360 | 7,657 | 8,366 | 8,775 | 10,655 | 12,946 | 4,225 | 4,832 | 4,094 | 3,564 | 5,502 | 43,330 | 8,519 | 9,795 | 11,603 | 12,890 | 11,116 | 5,555 | 2,369 | 174 |
Inventory | -20.3% | 2,134 | 2,677 | 2,451 | 2,513 | 3,061 | 3,119 | 1,953 | 1,710 | 822 | 368 | 793 | 956 | 289 | 385 | 1,284 | 1,235 | 759 | 311 | 320 | 319 | 304 |
Net PPE | -24.5% | 25.00 | 33.00 | 38.00 | 43.00 | 46.00 | 49.00 | 54.00 | 75.00 | 94.00 | 111 | 269 | 246 | 266 | 286 | 306 | 305 | 383 | 375 | 389 | 304 | 265 |
Goodwill | - | - | - | - | - | - | - | - | - | - | - | 11,893 | 11,988 | - | - | - | - | - | - | 1,564 | 1,564 | 1,564 |
Liabilities | 85.4% | 6,993 | 3,772 | 5,176 | 6,233 | 5,937 | 8,518 | 6,969 | 7,802 | 13,293 | 1,163 | 1,970 | 1,991 | 1,212 | 1,346 | 1,471 | 1,338 | 1,544 | 845 | 906 | 1,010 | 2,083 |
Current Liabilities | -3.6% | 1,271 | 1,319 | 1,432 | 1,997 | 2,178 | 4,012 | 1,733 | 1,693 | 1,826 | 1,159 | 1,970 | 1,805 | 983 | 1,074 | 1,157 | 983 | 1,148 | 410 | 459 | 529 | 1,569 |
Shareholder's Equity | -58.1% | 3,414 | 8,146 | 7,702 | 7,241 | 8,482 | 7,918 | 21,259 | 22,033 | 18,328 | 22,298 | 36,643 | 39,293 | 43,491 | 8,515 | 10,688 | 12,696 | 13,740 | 12,032 | 8,049 | 4,688 | 1,888 |
Retained Earnings | -5.1% | -98,313 | -93,566 | -93,990 | -94,363 | -93,191 | -93,724 | -81,270 | -80,447 | -84,103 | -78,802 | -64,281 | -61,266 | -56,726 | -54,083 | -50,709 | -48,565 | -47,858 | -45,511 | -41,455 | -39,070 | -36,018 |
Additional Paid-In Capital | 0.0% | 101,726 | 101,711 | 101,691 | 101,603 | 101,671 | 101,641 | 102,468 | 102,419 | 102,369 | 101,099 | 100,900 | 100,536 | 100,193 | 62,583 | 61,309 | 61,173 | 61,513 | 57,531 | 49,454 | 43,736 | 37,886 |
Shares Outstanding | 0.7% | 1,284 | 1,275 | 1,275 | 1,267 | 1,267 | 1,267 | 1,084 | 1,009 | 783 | 489 | 489 | 489 | 427 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 9,900 | - | - | - | 9,200 | - | - | - | 41,800 | - | - | - | 37,500 | - | - | - | 20,800 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 42.7% | -754 | -1,317 | -766 | -406 | -1,879 | -1,363 | -1,282 | -2,574 | -2,226 | -1,566 | -1,792 | -4,865 | -2,420 | -2,173 | -1,819 | -2,285 | -1,735 | -1,840 | -1,695 | -1,907 | -586 |
Share Based Compensation | - | 13.00 | - | - | - | 25.00 | - | - | - | - | - | - | - | - | - | -251 | 1,402 | 68.00 | 78.00 | 57.00 | 187 | 56.00 |
Cashflow From Investing | -100.0% | - | 20.00 | - | -2.14 | -1.65 | - | 10,004 | 1,990 | -7,003 | 2,096 | -145 | - | - | - | 6.00 | - | -40.73 | -7.97 | -104 | -54.12 | -4.82 |
Cashflow From Financing | - | - | - | 58.00 | - | -5,250 | 4,323 | - | -24.01 | 9,969 | -1* | - | 1* | 37,231 | 897 | 6.00 | 999 | 3,551 | 7,409 | 4,986 | 4,156 | 94.00 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | ||
Total revenue | $ 2,999,645 | $ 3,185,689 |
Cost of goods sold | ||
Total cost of goods sold | 1,820,645 | 1,850,387 |
Gross Profit | 1,179,000 | 1,335,302 |
Operating expenses | ||
Research and development | 3,168 | 62,734 |
Sales and marketing | 361,908 | 598,655 |
General and administrative | 1,834,669 | 2,050,252 |
Transaction costs related to pending disposition of business | 529,690 | 87,668 |
Loss on disposal of fixed assets | 3,366 | |
Total operating expenses | 2,732,801 | 2,799,309 |
Loss from operations | (1,553,801) | (1,464,007) |
Other income (expense): | ||
Change in fair value of warrant derivative liability | (3,268,588) | 1,898,100 |
Interest income, net | 75,645 | 98,998 |
Total other income (expense) | (3,192,943) | 1,997,098 |
Net income (loss) | $ (4,746,744) | $ 533,091 |
Net income (loss) per common share - basic | $ (3.71) | $ 0.42 |
Net income (loss) per common share - diluted | $ (3.71) | $ 0.42 |
Weighted average common shares outstanding - basic | 1,280,306 | 1,267,340 |
Weighted average common shares outstanding - diluted | 1,280,306 | 1,267,340 |
Nutritional Supplements [Member] | ||
Revenue | ||
Total revenue | $ 2,918,526 | $ 3,091,447 |
Cost of goods sold | ||
Total cost of goods sold | 1,776,479 | 1,781,827 |
Ocular Products [Member] | ||
Revenue | ||
Total revenue | 81,119 | 94,242 |
Cost of goods sold | ||
Total cost of goods sold | $ 44,167 | $ 68,560 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 5,605,035 | $ 6,359,646 |
Accounts receivable, net | 2,103,325 | 2,274,394 |
Inventories, net | 2,134,213 | 2,677,112 |
Prepaid expenses and other current assets | 539,209 | 573,780 |
Total current assets | 10,381,782 | 11,884,932 |
Property and equipment, net | 25,089 | 33,245 |
Total assets | 10,406,871 | 11,918,177 |
Current liabilities | ||
Accounts payable | 413,294 | 614,122 |
Accrued expenses | 857,805 | 704,912 |
Total current liabilities | 1,271,099 | 1,319,034 |
Warrant derivative liability – long-term | 5,721,688 | 2,453,100 |
Total liabilities | 6,992,787 | 3,772,134 |
Commitments and contingencies | ||
Stockholders’ equity | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized | ||
Common stock, $0.001 par value; 250,000,000 shares authorized; 1,284,156 shares and 1,275,238 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 1,284 | 1,275 |
Additional paid-in capital | 101,725,811 | 101,711,035 |
Accumulated deficit | (98,313,011) | (93,566,267) |
Total stockholders’ equity | 3,414,084 | 8,146,043 |
Total liabilities, preferred stock and stockholders’ equity | $ 10,406,871 | $ 11,918,177 |
 | Ms. Janet Hall |
---|---|
 | guardionhealth.com |
 | Pharmaceuticals |
 | 12 |